Semaglutide

Semaglutide is a GLP-1 receptor agonist, FDA-approved for type 2 diabetes and chronic weight management, with the most thoroughly studied protocol of any compound covered here. Off-label users typically run below the approval label, many settling at 0.25 mg once they reach a tolerable response, with GI tolerability and cost the main factors keeping doses there. Exploratory indications span a wide range, but most lack posted trial results — the off-label evidence base is thinner than the breadth of active research suggests.

Semaglutide

Research Evidence

Evidence shape

Semaglutide carries the highest tier of clinical evidence, with the strongest trials concentrated in type 2 diabetes and obesity — two indications backed by dozens of blinded studies across 72 distinct sponsors and over 800,000 enrolled participants. Results are posted for 11 indications including NAFLD and cognitive function in aging, though most of the 171 mapped indications are single-trial or exploratory with no posted results. Five indications — including CKD and solid tumors — have registered trials but no data at all.

Depthhow much
542 registered trials
253 completed · 74 with posted results · 238 recruiting / active · combined n=807722
Breadthhow many areas
180 indications mapped
10 with results · 166 thin / exploratory · 1 animal-only · 137 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
49 blinded with results · 68 distinct sponsors · AE rows aggregated from 67 trials · 20 linked publications on registered trials
Breadth and depth564 rows captured
Human
direct clinical signal
542
Animal
translational support
12
In vitro
mechanistic support
10
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
High Purity Peptides
HK
300 mg
$110.00
$0.367/mg
2
Vionex Peptides
UK
10 mg
$19.99
$2/mg
3
Peppyandme
US
20 mg
$45.00
$2.25/mg
4
Northline Labs
--
50 mg
$119.00
$2.38/mg
5
Biotechcompounds
US
30 mg
$80.00
$2.67/mg
6
Eternaaminos
US
20 mg
$54.95
$2.75/mg

price offers can be sorted by column

1-6 of 66

Dosing & Protocol

How Semaglutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 109
Typical dose
250 µg30 µg – 1.5 mg
50 µg
100 µg
250 µg
500 µg
1 mg
Frequency
weekly
Timing
unspecified
Route
subQ
Cycle
unspecified

Across 109 completed trials, registry dosing was 30 µg–1.5 mg weekly subQ.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
500 µg500 µg – 1 mg
50 µg
100 µg
250 µg
500 µg
1 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 500 µg–1 mg daily subQ (2 sources).

2 sources
Anecdotal
Community-reported real-world use · n = 510
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports highlight Semaglutide's use for weight management (82.2% positive out of 433 reports), type 2 diabetes control (90% positive out of 30 reports), and other metabolic health benefits (97.9% positive out of 47 reports). Specific dose hints from posts are not aggregated.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. •
  • • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. • Never share an OZEMPIC pen between patients , even if the needle is changed. •
  • • Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. •
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. •
  • • Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. OZEMPIC is not recommended in patients with severe gastroparesis. •
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if suspected and promptly seek medical advice. •
  • • Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. •
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedur…
Contraindications
  • • OZEMPIC is contraindicated in
  • • patients with: • A personal or family history of MTC or in
  • • patients with MEN 2 [see Warnings and Precautions (5.1) ] . • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angio…
  • • patients with MEN 2. • Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC.
Drug interactions
  • • Medications : OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution. (7.2)

Peptide feedback

0 forum replies

Live community discussion for Semaglutide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.